-+ 0.00%
-+ 0.00%
-+ 0.00%

60 DEGREES PHARMA ANNOUNCES IRB APPROVAL OF PHASE II STUDY TO EVALUATE TAFENOQUINE FOR CHRONIC BABESIOSIS

Reuters·01/28/2025 13:08:22

Please log in to view news